Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Filings indexed 707 across all filing types
Latest filing 2020-10-29 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2020-10-29 English
Outcome of Board Meeting
Regulatory Filings
2020-10-29 English
Updates
Regulatory Filings
2020-10-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an announcement for a conference call regarding Q2 & H1 FY21 results of Laurus Labs Limited. It includes details about the timing, dial-in numbers, and registration link for the call. There is no actual financial data or detailed report content present, only an invitation and logistical information for the earnings call. This matches the definition of a Call Transcript (CT) document type, which includes full text transcripts or announcements of company conference calls such as earnings calls. Although the transcript itself is not provided, the announcement of the call is closely related to the call transcript category rather than a financial report or other filing. The document length is short and does not contain financial statements or management discussion beyond the call invitation, so it is not an Interim Report or Earnings Release. Therefore, the best classification is Call Transcript (CT) with high confidence.
2020-10-26 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive textual content. The true document length is only 329 characters, which is very short and contains no financial data, report content, or announcements. It does not contain any report, announcement, or certification text. Given the lack of content and the presence of only image placeholders, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2020-10-26 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 113 characters, indicating it is extremely short and does not contain any report content. It is likely a placeholder or an announcement with no detailed information. According to the MENU VS MEAL RULE, such a short document without actual report content should be classified as a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Given the lack of any textual content or indication of report publication, the safest classification is Regulatory Filings (RNS) as a fallback category.
2020-10-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.